Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of January 2026
Date Filed: January 30, 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the cover page. The document references an exhibit (99.1) titled "ATH - Quarterly Activities/Appendix 4C Cash Flow Report" which likely contains these details, but the data itself is not present in the provided text.
Material Changes
The filing text does not provide information regarding material changes versus the prior comparable period.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. The document serves primarily as a cover sheet to incorporate exhibits by reference into existing Registration Statements (Form S-8 and Form F-3).
Investor Verification Checklist
- Review Exhibit 99.1 ("ATH - Quarterly Activities/Appendix 4C Cash Flow Report") for actual cash flow figures and operational updates.
- Verify the status of the referenced Registration Statements (Form S-8: 333-251073, 333-248980, 333-228671; Form F-3: 333-274816, 333-251647, 333-231417, 333-250076).
- Confirm the company's continued status as a development stage enterprise and its burn rate relative to available cash.